摘要
目的：观察CD3AK在头颈部恶性肿瘤的综合治疗中的效果。方法：81例头颈部恶性肿瘤分成CD3AK治疗组（n＝42）和对照组（n＝39），治疗组有术前、术后单用CD3AK细胞治疗，亦有术前化疗加用CD3AK细胞治疗；对照组有术前、术后单用LAK细胞治疗，有术前单用化疗。治疗前后检查肿瘤缩小情况，并检测外周血T细胞亚群和血清可溶性白细胞介素2受体水平。结果：CD3AK对舌癌的治疗效果最好，治疗组与对照组比较有显著性差异（P<0．01）；其次为喉癌与甲状腺癌，与对照组相比,有显著性差异（P<0．05）；再次为腮腺腺癌。各项免疫指标：CD3、CD4、CD8及CD4/CD8均有不同程度的提高；sIL2R水平有所下降。结论：CD3AK细胞治疗作为新的肿瘤过继免疫治疗，在头颈部恶性肿瘤的综合治疗中，毒副反应较少，疗效满意，有很好的推广前景。
To observe the effect of CD3AK cells in c ombined therapy on head and neck cancerMethod:8l cases of he ad and neck canc er were divided into treated group (n=42) and control group (n=39) In the trea ted group, there were CD3AK cells alone in preoperation and postoperation, and a1so CD3AK cells plus adjuvant chemotherapy In the control group, there were LAK ce1Is alone in the preoperation and postoperation, and also chemot herapy alone The size of neop1asm were examined , periphera1 blood T cell I su bsets and level of sIL2R were determined before and after treatment Resu1t:The effect of tongue carcinoma wi th CD3AK cells had best, its efficient rate of two groups had significant diff erence (P<0.01) The secondly, effect of laryngeal carcinoma and thyroid c arcinoma had batter ) its efficient rate of two groups had difference(P<O. O5) Th e third was parotid carcinoma CD3,CD4, CD8 T cells subsets and CD4/CD 8 ratio increased dissimilarly,meanwhi1e, the leve1 of sIL2R decreasedConc1usion: CD3AK ceI1s treatment is a new adjuvant immunotherapy, and one of th e method in combined therapy on head and neck cancer It is effectiveness and s afety We should genera1ize it
基金
广西教育厅科研基金
